Cantor Fitzgerald Reiterates Overweight Rating for Sanara MedTech (NASDAQ:SMTI)

Cantor Fitzgerald reissued their overweight rating on shares of Sanara MedTech (NASDAQ:SMTI) in a research note released on Wednesday morning,Benzinga reports. The brokerage currently has a $46.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Sanara MedTech’s FY2025 earnings at ($2.43) EPS.

Separately, HC Wainwright raised their price target on shares of Sanara MedTech from $50.00 to $51.00 and gave the company a “buy” rating in a research note on Wednesday.

Sanara MedTech Stock Down 3.3 %

Shares of NASDAQ:SMTI opened at $30.19 on Wednesday. The company’s fifty day moving average is $34.26 and its two-hundred day moving average is $33.74. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.02 and a current ratio of 2.23. Sanara MedTech has a 1-year low of $26.00 and a 1-year high of $39.08. The stock has a market capitalization of $263.89 million, a price-to-earnings ratio of -30.49 and a beta of 1.37.

Sanara MedTech (NASDAQ:SMTI) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%. The business had revenue of $26.31 million for the quarter, compared to the consensus estimate of $22.75 million. Equities analysts anticipate that Sanara MedTech will post -1.1 EPS for the current year.

Institutional Investors Weigh In On Sanara MedTech

Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in Sanara MedTech during the fourth quarter valued at approximately $1,005,000. Fifth Third Bancorp acquired a new stake in shares of Sanara MedTech during the fourth quarter worth $898,000. Renaissance Technologies LLC lifted its holdings in shares of Sanara MedTech by 152.9% during the fourth quarter. Renaissance Technologies LLC now owns 35,400 shares of the company’s stock valued at $1,175,000 after purchasing an additional 21,400 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Sanara MedTech by 234.5% in the fourth quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company’s stock worth $451,000 after buying an additional 9,516 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Sanara MedTech by 116.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 15,925 shares of the company’s stock worth $529,000 after acquiring an additional 8,567 shares in the last quarter. 8.10% of the stock is owned by institutional investors and hedge funds.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.